MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Just Happened with Praxis's Vormatrigine Program

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Just Happened with BD and Waters

4 months ago

What Just Happened with Chegg's NYSE Compliance

1 months ago

What Just Happened with Generate Biomedicines' IPO

4 months ago

What Just Happened with Trump's Tariffs, and Why Does it Matter

5 months ago

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions

Ovid Therapeutics was upgraded to Buy as OV329 cleared safety hurdles at higher doses. The next-gen GABA-aminotransferase inhibitor shows best-in-class potential vs Sabril, with Phase 2 expansions tar...

OVID

Stock News•1 months ago

Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

Praxis Precision Medicines shares may face volatility after the Phase 2/3 POWER1 study of vormatrigine failed to meet its primary endpoint for treating focal onset seizures. The company is now reasses...

PRAX

Stock News•2 months ago

NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care

NeuroPace is refocusing its business strategy on the RNS System, supported by new AI-driven ECoG Assistant tools and cloud infrastructure upgrades. The company now faces critical upcoming milestones r...

NPCE

Stock News•2 months ago

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CAMP4 Therapeutics reported that its lead candidate, CMP-002, significantly improved seizure thresholds and severity in a SYNGAP1-related disorder mouse model. These preclinical results provide a pote...

CAMP